+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of EIK1001 combined with Pembrolizumab compared to a placebo plus Pembrolizumab as the first treatment for patients with advanced melanoma. This is a multicenter, randomized, double-blind phase 23 trial that includes dose optimization and expansion parts to assess these therapies. The trial is sponsored by Eikon Therapeutics and targets patients eligible for standard Pembrolizumab therapy. Participants are randomly assigned to one of three groups one receiving a placebo with Pembrolizumab, another receiving a selected dose of EIK1001 plus Pembrolizumab, and a third receiving a different dose of EIK1001 plus Pembrolizumab. EIK1001 is a drug that activates specific immune receptors, and Pembrolizumab is an immune checkpoint inhibitor. The study includes dose optimization in the early phase and expands to larger groups for further evaluation. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, blood tests to monitor organ function, and evaluations of any side effects. Researchers will measure outcomes such as progression-free survival, overall survival, and objective tumor response over a period of up to five years. Safety and adverse events will be closely monitored, particularly during the dose optimization phase. Participants may be followed for up to five years to track long-term effects and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
127 locations